Rosalind Advisors, Inc. Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001622627

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q4 2023 · 29 positions · Total reported value $121.42M · Top-10 concentration 62.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 54.8% · 9 new · 11 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): +4.7% · vs SPY +2.5% · Prev Value $269.06M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -5.8% · vs SPY -7.9% · Latest Value $244.66M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2023 13F filing, Rosalind Advisors, Inc. disclosed 29 equity positions with a combined reported value of $121.42M. The filing implies a focused portfolio: its ten largest positions account for 62.6% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2023 were LYRA ($9.90M), MYO ($9.62M), ATXS ($8.67M). By sector, the heaviest allocations are Health Care 70.0%, Other 30.0%.

Versus the prior quarter, Rosalind Advisors, Inc. opened 9 new positions, trimmed 11 and fully exited 3, a turnover rate of 54.8% of positions.

The largest new positions opened in Q4 2023 were LYRA ($9.90M), MYO ($9.62M), ATXS ($8.67M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2023)

  • LYRA LYRA THERAPEUTICS INC · $9.90M
  • MYO MYOMO INC · $9.62M
  • ATXS ASTRIA THERAPEUTICS INC · $8.67M
  • XERS XERIS BIOPHARMA HOLDINGS INC · $8.33M
  • VRDN VIRIDIAN THERAPEUTICS INC · $7.85M
  • CMPS COMPASS PATHWAYS PLC · $6.99M
  • SRPT SAREPTA THERAPEUTICS INC · $6.37M
  • OPTN OPTINOSE INC · $6.30M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Rosalind Advisors, Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-13 J DELCATH SYSTEMS, INC. 27,502 — SEC filing
2026-10-13 Conversion DELCATH SYSTEMS, INC. 3,627 — SEC filing

All insider transactions →

Fund Profile

Rosalind Advisors, Inc. is an SEC-registered 13F filer. As of Q2 2026 it reported 33 US equity positions with a combined value of $269.06M. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Portfolio Structure

  • 33 positions · $269.06M reported value (Q2 2026)
  • Top 10 holdings = 74.1% of reported value
  • Largest position: DCTH (DELCATH SYS INC) at 15.4%
  • Average position size: $8.15M

Sector Tilt

  • Health Care 94.7%
  • Industrials 5.3%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 7 added, 12 reduced, 8 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 70.0%
Other 30.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.89M $9.90M 8.15%
8.15%
New
2 1.92M $9.62M 7.92%
7.92%
New
3 1.13M $8.67M 7.14%
7.14%
New
4 3.54M $8.33M 6.86%
6.86%
New
5 360.33K $7.85M 6.46%
6.46%
New
6 798.50K $6.99M 5.75%
5.75%
New
7 114.80K $6.37M 5.24%
5.24%
New
8 4.89M $6.30M 5.19%
5.19%
New
9 606.75K $6.17M 5.08%
5.08%
New
10 25.00K $5.78M 4.76%
4.76%
New
11 2.01M $5.56M 4.58%
4.58%
New
12 250.00K $4.97M 4.09%
4.09%
New
13 1.59M $4.65M 3.83%
3.83%
New
14 533.33K $4.53M 3.73%
3.73%
New
15 1.04M $4.32M 3.56%
3.56%
New
16 300.00K $3.67M 3.03%
3.03%
New
17 4.00M $2.88M 2.37%
2.37%
New
18 925.19K $2.60M 2.14%
2.14%
New
19 1.86M $2.50M 2.06%
2.06%
New
20 16.80K $2.12M 1.74%
1.74%
New
21 607.80K $1.83M 1.51%
1.51%
New
22 312.09K $1.60M 1.32%
1.32%
New
23 196.30K $1.01M 0.83%
0.83%
New
24 60.00K $804.60K 0.66%
0.66%
New
25 900.00K $602.00K 0.50%
0.50%
New
26 758.97K $557.84K 0.46%
0.46%
New
27 500.00K $465.00K 0.38%
0.38%
New
28 200.00K $422.00K 0.35%
0.35%
New
29 900.90K $363.06K 0.30%
0.30%
New

FAQ

What did Rosalind Advisors, Inc. buy in 2023-Q4?

In its 2023-Q4 13F filing, Rosalind Advisors, Inc. reported 29 equity positions worth $121.42M in aggregate; its largest disclosed positions were LYRA ($9.90M), MYO ($9.62M), ATXS ($8.67M).

How large is Rosalind Advisors, Inc.'s portfolio?

Rosalind Advisors, Inc. reported $121.42M of long equity holdings across 29 positions as of 2023-Q4. Top-10 holdings account for 62.6% of reported value.

What is Rosalind Advisors, Inc.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/rosalind-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →